Malarone

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial presented as a 250 mg atovaquone / 100 mg proguanil hydrochloride tablet for oral use. It is employed to prevent malaria infection and to treat acute uncomplicated malaria caused by Plasmodium species in travelers and patients at risk, including those visiting endemic regions globally.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Malarone is an antimalarial used for malaria chemoprophylaxis and treatment of acute infections. - Malaria prophylaxis: prevents infection in travelers and residents of endemic regions. - Uncomplicated P. falciparum malaria treatment: clears parasites and resolves symptoms. - Uncomplicated malaria caused by other Plasmodium species: provides effective parasite clearance.

Malarone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial pain. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools. - Vomiting: expulsion of stomach contents. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hemolysis in G6PD deficiency: rapid destruction of red blood cells. - Anaphylaxis: life‑threatening allergic response. - Neutropenia: marked reduction in white blood cells.

Before prescribing Malarone, clinicians should consider several safety measures. - Renal or hepatic assessment: evaluate function before initiating therapy. - Hypersensitivity: avoid in patients with known allergy to atovaquone or proguanil. - Pregnancy and lactation: use only if benefit outweighs risk, as safety data are limited. - Monitoring: watch for signs of severe skin reactions or hepatic dysfunction during treatment. - Drug interactions: review concomitant medications that may affect absorption or metabolism. - Store at below 25°C: keep in the original pack, protect from moisture.

Malarone can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism, markedly lowering atovaquone and proguanil plasma levels. - Antacids containing aluminum or magnesium: decrease atovaquone absorption when taken together. - Certain antiretrovirals (e.g., zidovudine): may increase toxicity risk.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., amiodarone): may raise atovaquone concentrations. - CYP3A4 inhibitors (e.g., ketoconazole): can increase proguanil levels. - Warfarin: may require INR monitoring due to potential interaction.